Holen Sie sich die Stockscreener-App
4.68
1.47%
-0.07
Handel nachbörslich:
4.65
-0.03
-0.64%
Schlusskurs vom Vortag:
$4.75
Offen:
$4.75
24-Stunden-Volumen:
616.72K
Relative Volume:
0.63
Marktkapitalisierung:
$194.66M
Einnahmen:
$134.48M
Nettoeinkommen (Verlust:
$-38.94M
KGV:
-4.9087
EPS:
-0.9534
Netto-Cashflow:
$-19.34M
1W Leistung:
+0.43%
1M Leistung:
-33.43%
6M Leistung:
-29.52%
1J Leistung:
-45.33%
1-Tages-Spanne:
$4.63
$4.77
1-Wochen-Bereich:
$4.61
$4.99
52-Wochen-Spanne:
$4.48
$13.22
Rxsight Inc Stock (RXST) Company Profile
Firmenname
Rxsight Inc
Sektor
Branche
Telefon
949-521-7822
Adresse
100 COLUMBIA STREET, ALISO VIEJO
Compare RXST vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
4.68 | 193.82M | 134.48M | -38.94M | -19.34M | -0.9534 |
ABT
Abbott Laboratories
|
97.50 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
86.38 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.43 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
42.60 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.15 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Eingeleitet | William Blair | Mkt Perform |
| 2025-07-15 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-07-10 | Herabstufung | Jefferies | Buy → Hold |
| 2025-07-09 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-07-09 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-07-09 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-04-15 | Eingeleitet | Piper Sandler | Neutral |
| 2025-04-09 | Herabstufung | UBS | Buy → Neutral |
| 2025-04-04 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2025-04-03 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-12-20 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | Eingeleitet | UBS | Buy |
| 2024-10-29 | Eingeleitet | Jefferies | Buy |
| 2024-08-20 | Bestätigt | Needham | Buy |
| 2024-08-06 | Bestätigt | Needham | Buy |
| 2024-05-07 | Bestätigt | BTIG Research | Buy |
| 2023-12-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-12 | Eingeleitet | Stifel | Buy |
| 2023-12-04 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-04-13 | Eingeleitet | Oppenheimer | Outperform |
| 2022-12-12 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-08 | Eingeleitet | Needham | Buy |
Alle ansehen
Rxsight Inc Aktie (RXST) Neueste Nachrichten
Is the New Setup at RxSight (NASDAQ:RXST) Sustainable? - kalkinemedia.com
RxSight stock faces a lower Jefferies target at USD 5.75 - AD HOC NEWS
RxSight Realigns Top Management - Medical Product Outsourcing
RxSight stock falls 1.62 percent as target cuts mount - AD HOC NEWS
RxSight's Utilization-Growth Upside Faces Structural, Competitive Headwinds, BofA Says - marketscreener.com
(RXST) Risk Channels and Responsive Allocation - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: RxSight (RXST) and Armata Pharmaceuticals (ARMP) - The Globe and Mail
RxSight Price Target Cut to $5.75/Share From $6.50 by Jefferies - Moomoo
RxSight stock falls as price targets are cut - AD HOC NEWS
BofA Adjusts Price Target on RxSight to $5.50 From $6.50 - Yahoo Finance
RXSIGHT, INC. : JEFFERIES CUTS TARGET PRICE TO $5.75 FROM $6.50 - Bitget
RxSight, Inc. (RXST) Stock Analysis: Evaluating the 46% Potential Upside in Medical Device Innovation - DirectorsTalk Interviews
RxSight, Inc. (RXST) insider now holds 235,516 shares after option exercise - Stock Titan
The Technical Signals Behind (RXST) That Institutions Follow - Stock Traders Daily
Alcon, RxSight Form Collaboration to Develop Adjustable PCIOLs - Medical Product Outsourcing
Midday Stock Roundup: Skyworks Rises on Qorvo News - Orange County Business Journal
RxSight (NASDAQ: RXST) CFO swaps 258K options, cuts strike to $6.375 with no share change - Stock Titan
RxSight (NASDAQ: RXST) COO swaps high-priced options for new $6.375 grants - Stock Titan
RxSight (RXST) CMO exchanges higher-priced options for new $6.375 grants - Stock Titan
RxSight (NASDAQ:RXST) Faces a Crucial Test on the Road to Scale - Kalkine Media
RxSight at wells fargo healthcare conference: reset centers on LAL growth - Investing.com Canada
RxSight (RXST) ends employee option swap after 91.9% take-up - Stock Titan
RXST Form 4 FilingsRxSight, Inc. SEC Form 4 - Stock Titan
RXST stock slips as insider selling and cash level draw attention - AD HOC NEWS
RxSight Officer Mark Wilterding to Sell 7,765 Shares Worth $54,044.40 to Cover Tax Withholding - Kalkine Media
RxSight stock edges higher after insider tax sales and Q2 beat - AD HOC NEWS
RxSight CFO Mark Wilterding sells $54,044 in company stock By Investing.com - Investing.com South Africa
RxSight COO Ilya Goldshleger sells $14,205 in company stock By Investing.com - Investing.com South Africa
RxSight CMO Ronald Kurtz sells $35,496 in shares for tax By Investing.com - Investing.com Australia
RxSight CFO Mark Wilterding sells $54,044 in company stock - Investing.com
RxSight COO Ilya Goldshleger sells $14,205 in company stock - Investing.com
RxSight CMO Ronald Kurtz sells $35,496 in shares for tax - Investing.com India
RxSight chief business development officer Eric Weinberg sells $14,205 in stock - Investing.com
RxSight (NASDAQ: RXST) officer plans 5,100-share sale to cover taxes - Stock Titan
RSU vesting at RxSight (NASDAQ: RXST) prompts insider share sale - Stock Titan
RxSight (RXST) officer to sell shares for taxes - Stock Titan
RxSight (RXST) CFO sells shares to cover RSU taxes - Stock Titan
RxSight (RXST) CMO vests 13,425 units, sells shares for taxes - Stock Titan
RxSight (RXST) COO sells 2,041 shares after RSU vest - Stock Titan
RxSight (RXST) exec’s stock sale only covers taxes - Stock Titan
Price to earnings forward of RxSight, Inc. – NASDAQ:RXST - TradingView
(RXST) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
RxSight stock holds in the lower single digits as losses narrow on stronger quarterly revenue - AD HOC NEWS
RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference - GlobeNewswire
RxSight (NASDAQ: RXST) refreshes documents for option exchange - Stock Titan
Tocqueville Asset Management L.P. Makes New Investment in RxSight, Inc. $RXST - MarketBeat
Steven Cohen’s Point72 discloses RxSight (RXST) stake - Stock Titan
RxSight (RXST) Q2 2026 Results: The Bottom-Line Figure Outpaces Its Comparison at the Close; Price Move - vinanet.vn
RxSight (RXST) Market: Moves 1.88% Higher to $6.49 in the Current Update; Boundary Watch: Support at $6.17 and Resistance at $6.81 Frame the Range on the DayATR Trailing Stop - vinanet.vn
Vitruvian Partners LLP Purchases New Holdings in RxSight, Inc. $RXST - MarketBeat
RxSight (RXST) Quarterly Figures: The Bottom-Line Figure Outpaces Its Comparison in Latest Trading; Price Reaction: The Stock Ends Down 1.70% in the Latest SessionGuidance Upgrade Report - Vinanet
Finanzdaten der Rxsight Inc-Aktie (RXST)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.26%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):